Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 6, 2003, Pages 601-604

  Perry, Stephanie L ^a   O'Shea, Susan I ^a   Ortel, Thomas L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Activated partial thromboplastin time; Antiphospholipid antibody syndrome; Ecarin clot time; Lepirudin

Indexed keywords

DANAPAROID; LEPIRUDIN;

ADULT; ANAMNESIS; ANTIPHOSPHOLIPID ANTIBODY SYNDROME; ARTICLE; BLOOD SAMPLING; CASE REPORT; HOSPITALIZATION; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VASCULAR DISEASE;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; DRUG MONITORING; ENDOPEPTIDASES; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; WHOLE BLOOD COAGULATION TIME;

EID: 0042833025     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200309000-00014     Document Type: Article

References (18)

1. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79:1-7.
2. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70:554-561.
3. Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999; 100:587-593.
4. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, et al., for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation 1999; 99:73-80.
5. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843.
6. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy. The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122:799-807.
7. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346:752-763.
8. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74:1185-1190.
9. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309-1311.
10. Triplett DA, Stocker KF, Unger GA, Barna LK. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70:925-931.
11. Koster A, Hansen R, Kuppe H, Hetzer R, Crystal GJ, Mertzlufft F. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J Cardiothor Vasc Anesth 2000; 14:243-248.
12. Kornalik F, Blomback B. Prothrombin activation induced by Ecarin - a prothrombin converting enzyme from Echis carinatus venom. Thromb Res 1975; 6:57-63.
13. Morita T, Iwanaga S, Suzuki T. The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venon and characterization of the new active intermediates. J Biochem (Tokyo) 1976; 79:1089-1108.
14. Briet E, Noyes CM, Roberts HR, Griffith MJ. Cleavage and activation of human prothrombin by Echis carinatus venom. Thromb Res 1982; 27:591-600.
15. Nowak G, Bucha E. A new method for the therapeutical monitoring of hirudin [Abstract]. Thromb Haemost 1993; 69:1306.
16. Walenga JM, Fasanella AR, Iqbal O, Hoppensteadt DA, Ahmad S, Wallis DE, Bakhos M. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999; 25(suppl 1):61-66.
17. Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 1993; 70:286-288.
18. Groce JB, Gal P, Douglas JB, Steuterman MC. Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time. Clin Pharm 1987; 6:216-222.